Physician profile
Kory Ryan Bishop
NPI 1326435405
$2,573.88
in general payments reported to CMS, 2019-2025
33 companies · $828 in 2025
The $828 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $64.17 · 2023: $299 · 2024: $718 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $381.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $364.20 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $336.54 | 2024-2025 | |
| Novo Nordisk INC | $267.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $183.84 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $107.65 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $88.89 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $86.43 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $74.77 | 2023-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $71.94 | 2025 | Nuzyra, Xhance |
| Novartis Pharmaceuticals Corporation | $65.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.67 | 2019-2023 | Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $49.95 | 2023-2024 | Xarelto, Spravato |
| Xeris Pharmaceuticals, INC. | $47.00 | 2023-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $45.40 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $31.86 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.16 | 2024-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $25.63 | 2025 | Zenpep |
| Sanofi Pasteur INC. | $22.99 | 2019 | |
| Corcept Therapeutics | $21.94 | 2024 | Korlym |
| Dynavax Technologies Corporation | $19.34 | 2024 | Heplisav-B |
| Antares Pharma, INC. | $19.12 | 2025 | Xyosted |
| Mayne Pharma Commercial LLC | $18.48 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.38 | 2024 | Eliquis |
| Genentech USA, INC. | $18.36 | 2019 | |
| Dexcom, INC. | $17.74 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.98 | 2025 | Auvelity |
| Amarin Pharma, INC. | $16.33 | 2020 | |
| Madrigal Pharmaceuticals | $15.33 | 2025 | Rezdiffra |
| Allergan, INC. | $14.83 | 2019 | |
| Currax Pharmaceuticals LLC | $12.79 | 2023 | Contrave |
| Strongbridge US INC. | $11.99 | 2020 | |
| Shire North American Group INC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kory Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.